Literature DB >> 24116893

Human T cell leukaemia virus type 2 tax protein mediates CC-chemokine expression in peripheral blood mononuclear cells via the nuclear factor kappa B canonical pathway.

C S Barrios1, L Castillo, H Zhi, C-Z Giam, M A Beilke.   

Abstract

Retroviral co-infections with human immunodeficiency virus type-1 (HIV-1) and human T cell leukaemia virus type 1 (HTLV-1) or type 2 (HTLV-2) are prevalent in many areas worldwide. It has been observed that HIV-1/HTLV-2 co-infections are associated with slower rates of CD4(+) T cell decline and delayed progression to AIDS. This immunological benefit has been linked to the ability of Tax2, the transcriptional activating protein of HTLV-2, to induce the expression of macrophage inflammatory protein (MIP)-1α/CCL3, MIP-1β/CCL4 and regulated upon activation normal T cell expressed and secreted (RANTES)/CCL5 and to down-regulate the expression of the CCR5 co-receptor in peripheral blood mononuclear cells (PBMCs). This study aimed to assess the role of Tax2-mediated activation of the nuclear factor kappa B (NF-κB) signalling pathway on the production of the anti-viral CC-chemokines MIP-1α, MIP-1β and RANTES. Recombinant Tax1 and Tax2 proteins, or proteins expressed via adenoviral vectors used to infect cells, were tested for their ability to activate the NF-κB pathway in cultured PBMCs in the presence or absence of NF-κB pathway inhibitors. Results showed a significant release of MIP-1α, MIP-1β and RANTES by PBMCs after the activation of p65/RelA and p50. The secretion of these CC-chemokines was significantly reduced (P < 0·05) by canonical NF-κB signalling inhibitors. In conclusion, Tax2 protein may promote innate anti-viral immune responses through the activation of the canonical NF-κB pathway.
© 2013 British Society for Immunology.

Entities:  

Keywords:  CC-chemokines; HTLV-2; NF-κB pathway; Tax2; innate immunity

Mesh:

Substances:

Year:  2014        PMID: 24116893      PMCID: PMC3898558          DOI: 10.1111/cei.12213

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  45 in total

1.  Uveitis associated with human T lymphotropic virus type I: seroepidemiologic, clinical, and virologic studies.

Authors:  M Mochizuki; T Watanabe; K Yamaguchi; K Tajima; K Yoshimura; S Nakashima; M Shirao; S Araki; N Miyata; S Mori
Journal:  J Infect Dis       Date:  1992-10       Impact factor: 5.226

2.  Mutational analysis of human T-cell leukemia virus type 2 Tax.

Authors:  T M Ross; A C Minella; Z Y Fang; S M Pettiford; P L Green
Journal:  J Virol       Date:  1997-11       Impact factor: 5.103

3.  C-C chemokines, pivotal in protection against HIV type 1 infection.

Authors:  D Zagury; A Lachgar; V Chams; L S Fall; J Bernard; J F Zagury; B Bizzini; A Gringeri; E Santagostino; J Rappaport; M Feldman; S J O'Brien; A Burny; R C Gallo
Journal:  Proc Natl Acad Sci U S A       Date:  1998-03-31       Impact factor: 11.205

4.  HTLV-I and HTLV-II virus expression increase with HIV-1 coinfection.

Authors:  M A Beilke; S Japa; D G Vinson
Journal:  J Acquir Immune Defic Syndr Hum Retrovirol       Date:  1998-04-15

5.  Inactivation of IkappaBbeta by the tax protein of human T-cell leukemia virus type 1: a potential mechanism for constitutive induction of NF-kappaB.

Authors:  T A McKinsey; J A Brockman; D C Scherer; S W Al-Murrani; P L Green; D W Ballard
Journal:  Mol Cell Biol       Date:  1996-05       Impact factor: 4.272

6.  [HABA (HTLV-I associated bronchiolo-alveolar disorder)].

Authors:  I Kimura
Journal:  Nihon Kyobu Shikkan Gakkai Zasshi       Date:  1992-05

7.  Protective mucosal immunity elicited by targeted iliac lymph node immunization with a subunit SIV envelope and core vaccine in macaques.

Authors:  T Lehner; Y Wang; M Cranage; L A Bergmeier; E Mitchell; L Tao; G Hall; M Dennis; N Cook; R Brookes; L Klavinskis; I Jones; C Doyle; R Ward
Journal:  Nat Med       Date:  1996-07       Impact factor: 53.440

8.  Human T-cell lymphotropic virus type 1 Tax mediates enhanced transcription in CD4+ T lymphocytes.

Authors:  G C Newbound; J M Andrews; J P O'Rourke; J N Brady; M D Lairmore
Journal:  J Virol       Date:  1996-04       Impact factor: 5.103

9.  Identification of RANTES, MIP-1 alpha, and MIP-1 beta as the major HIV-suppressive factors produced by CD8+ T cells.

Authors:  F Cocchi; A L DeVico; A Garzino-Demo; S K Arya; R C Gallo; P Lusso
Journal:  Science       Date:  1995-12-15       Impact factor: 47.728

Review 10.  An HTLV-I/II vaccine: from animal models to clinical trials?

Authors:  G de Thé; M Kazanji
Journal:  J Acquir Immune Defic Syndr Hum Retrovirol       Date:  1996
View more
  4 in total

1.  MicroRNA-570-3p regulates HuR and cytokine expression in airway epithelial cells.

Authors:  Alanna N Roff; Timothy J Craig; Avery August; Cristiana Stellato; Faoud T Ishmael
Journal:  Am J Clin Exp Immunol       Date:  2014-08-15

2.  Comparison of cytokine expressions in acute myocardial infarction and stable angina stages of coronary artery disease.

Authors:  Wenwen Yan; Siwan Wen; Lemin Wang; Qianglin Duan; Lin Ding
Journal:  Int J Clin Exp Med       Date:  2015-10-15

Review 3.  Co-Infection and Cancer: Host-Pathogen Interaction between Dendritic Cells and HIV-1, HTLV-1, and Other Oncogenic Viruses.

Authors:  Tania H Mulherkar; Daniel Joseph Gómez; Grace Sandel; Pooja Jain
Journal:  Viruses       Date:  2022-09-14       Impact factor: 5.818

4.  Minimally invasive implantation and decreased inflammation reduce osteoinduction of biomaterial.

Authors:  Zifan Zhao; Qin Zhao; Bin Gu; Chengcheng Yin; Kailun Shen; Hua Tang; Haibin Xia; Xiaoxin Zhang; Yanbing Zhao; Xiangliang Yang; Yufeng Zhang
Journal:  Theranostics       Date:  2020-02-18       Impact factor: 11.556

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.